App-Quantinova.ai

TAMOXIFEN CAN REDUCE MITOCHONDRIAL RESPIRATION, ONCOGENIC JAK-STAT SIGNALING AND MUTANT ALLELE BURDEN IN A SUBSET OF PATIENTS WITH MYELOPROLIFERATIVE NEOPLASMS – RESULTS OF THE TAMARIN PHASE II STUDY

Zijian Fang - European Hematology Association (EHA) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Myeloid neoplasms

Afimoxifene

ACALABRUTINIB ± OBINUTUZUMAB VS OBINUTUZUMAB + CHLORAMBUCIL IN TREATMENT-NAÏVE CHRONIC LYMPHOCYTIC LEUKEMIA: ELEVATE-TN 4-YEAR FOLLOW-UP

Jeff Sharman - European Hematology Association (EHA) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Chronic Lymphocytic Leukemia

ACP-196

SECOND-LINE BOSUTINIB FOR PATIENTS WITH CHRONIC PHASE CHRONIC MYELOID LEUKEMIA : FINAL 10-YEAR RESULTS OF A PHASE 1/2 STUDY

Carlo Gambacorti-Passerini - European Hematology Association (EHA) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Chronic Myelogenous Leukemia

Bosutinib

BRENTUXIMAB VEDOTIN WITH CHEMOTHERAPY FOR PATIENTS WITH PREVIOUSLY UNTREATED, STAGE III OR IV CLASSICAL HODGKIN LYMPHOMA: A 5-YEAR UPDATE OF THE PHASE 3 ECHELON-1 STUDY (NCT01712490)

Martin Hutchings - European Hematology Association (EHA) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Hodgkin's Lymphoma

Adcetris

XENOGRAFT MODELLING OF DRIVING MOLECULAR EVENTS IN BURKITT LYMPHOMA

Mankraran Singh - European Hematology Association (EHA) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Burkitt lymphoma

N/A

UNCERTAINTY ABOUT THE FUTURE: INSIGHTS FROM OLDER PATIENTS WITH ACUTE MYELOID LEUKAEMIA (AML) ON DIFFERENT TREATMENT PATHS

Roland B. Walter - European Hematology Association (EHA) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Acute myelocytic leukemia

N/A

FIXED-DURATION IBRUTINIB AND VENETOCLAX (I+V) VERSUS CHLORAMBUCIL PLUS OBINUTUZUMAB (CLB+O) FOR FIRST-LINE (1L) CHRONIC LYMPHOCYTIC LEUKEMIA (CLL): PRIMARY ANALYSIS OF THE PHASE 3 GLOW STUDY

Arnon Kater - European Hematology Association (EHA) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Chronic Lymphocytic Leukemia

Obinutuzumab

AN AUDIT OF DIAGNOSIS AND MANAGEMENT OF PE IN DGH AND LITERATURE REVIEW.

Tariq Memon - European Hematology Association (EHA) , 2021

Therapeutic Area

Disease

Drug/Treatment

Genetic Disorder

Cataract 6, multiple types

N/A

THE DIAGNOSIS, TREATMENT AND MONITORING OF PATIENTS WITH CHRONIC MYELOID LEUKAEMIA: THE IMPACT OF ELN GUIDELINES ON CLINICAL PRACTICE IN A DISTRICT GENERAL HOSPITAL

Sumitha Nyomi Nanayakkara - European Hematology Association (EHA) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Chronic Myelogenous Leukemia

L-Tyrosine

THE INCREASING INCIDENCE AND PREVALENCE OF HYPEREOSINOPHILIC SYNDROME (HES) IN THE UK

Gema Requena - European Hematology Association (EHA) , 2021

Therapeutic Area

Disease

Drug/Treatment

Genetic Disorder

Hypereosinophilic Syndrome

N/A

PIRTOBRUTINIB (LOXO-305), A NEXT GENERATION, HIGHLY SELECTIVE, NON-COVALENT BTK INHIBITOR IN PREVIOUSLY TREATED MCL, WM AND OTHER NHLS: RESULTS FROM THE PHASE 1/2 BRUIN STUDY

Nirav N. Shah - European Hematology Association (EHA) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

B cell lymphomas

N/A

ELIGIBILITY FOR EMERGING THERAPIES IN SICKLE CELL DISEASE

Sona M Vora - European Hematology Association (EHA) , 2021

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

Sickle cell anemia

Hydroxycarbamide

A UNIFIED CLASSIFICATION AND RISK STRATIFICATION ALGORITHM TO SUPPORT CLINICAL DECISIONS IN ACUTE MYELOID LEUKEMIA

Yanis Tazi - European Hematology Association (EHA) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Acute myelocytic leukemia

N/A

A PROSPECTIVE, NON-INTERVENTIONAL, MULTINATIONAL STUDY OF REAL-LIFE STANDARD OF CARE IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA WITH ≥3 PRIOR LINES OF THERAPY: INTERIM DATA FROM LOCOMMOTION

Maria-Victoria Mateos - European Hematology Association (EHA) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Multiple Myeloma

N/A

SYSTEMATIC LITERATURE REVIEW OF THE EFFICACY AND SAFETY OF MAINTENANCE THERAPIES FOR ADULTS WITH ACUTE MYELOID LEUKEMIA IN COMPLETE REMISSION WHO ARE INELIGIBLE FOR HEMATOPOIETIC STEM CELL TRANSPLANT

Beatrice Suero - European Hematology Association (EHA) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Acute myelocytic leukemia

N/A

BCMA-DIRECTED THERAPY IN MULTIPLE MYELOMA: EFFECT OF ONLINE EDUCATION ON CLINICIAN KNOWLEDGE AND CONFIDENCE

Amanda Taylor - European Hematology Association (EHA) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Multiple Myeloma

N/A

ECHELON-2, (NCT01777152), 5-YEAR RESULTS OF A RANDOMISED, DOUBLE-BLIND, PHASE 3 STUDY OF FRONTLINE BRENTUXIMAB VEDOTIN + CHP VS CHOP IN PATIENTS WITH CD30-POSITIVE PERIPHERAL T-CELL LYMPHOMA

Eva Domingo Domnech - European Hematology Association (EHA) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Peripheral T-cell lymphoma

Adcetris

A PHASE III TRIAL (GO42909) EVALUATING MOSUNETUZUMAB IN COMBINATION WITH LENALIDOMIDE (M-LEN) VERSUS RITUXIMAB-LENALIDOMIDE (R-LEN) IN PATIENTS WITH RELAPSED/REFRACTORY (R/R) FOLLICULAR LYMPHOMA (FL)

Christian W. Scholz - European Hematology Association (EHA) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Cytokine release syndrome

Lenalidomide

DASATINIB AND NAVITOCLAX REVERSE GLUCOCORTICOID RESISTANCE IN PRE-T-CELL RECEPTOR ACTIVATED T-CELL ACUTE LYMPHOBLASTIC LEUKAEMIA

Alistair Poll - European Hematology Association (EHA) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

T-cell acute lymphoblastic leukemia

Glucocorticoid

QUANTIFYING PATIENT PREFERENCES FOR TYROSINE KINASE INHIBITORS IN CHRONIC MYELOID LEUKEMIA: A DISCRETE-CHOICE EXPERIMENT

Bradley Mason - European Hematology Association (EHA) , 2021

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

Chronic Myelogenous Leukemia

L-Tyrosine

Filters

45280 Abstracts